Literature DB >> 23117818

Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells.

Rajash Pallai1, Aishwarya Bhaskar, Valerie Sodi, Lyndi M Rice.   

Abstract

Cancerous inhibitor of protein phosphatase 2A (CIP2A) has been identified as a proto-oncogene that is overexpressed in various types of human cancers. CIP2A acts by inhibiting protein phosphatase 2A-dependent destabilization of c-Myc, resulting in increased cell proliferation. Here, we have characterized the proximal promoter region of the human CIP2A gene in cervical, endometrial and liver carcinoma cells. The 5' flanking minimal proximal promoter of the CIP2A gene consists of putative binding sites for Ets1 and Elk1 in forward and reverse orientations. Here, we show that Ets1 and Elk1 binding is essential for CIP2A basal expression in several urogenital cancer cell lines. Interestingly, both Ets1 and Elk1 are required together for CIP2A expression, as siRNA knockdown of Ets1 and Elk1 together decreased CIP2A gene transcription, whereas knockdown of Ets1 or Elk1 alone had no effect. Moreover, ectopic expression of Ets1 and Elk1 together increased CIP2A expression. To gain physiological significance of the Ets1 and Elk1 regulation we observed, a panel of matched human cervical carcinoma samples was analyzed for the expression of CIP2A and Ets1 and/or Elk1. We found a direct correlation between the levels of CIP2A and the levels of Ets1 and Elk1. Our results suggest that the binding of Ets1 and Elk1 together to the proximal CIP2A promoter is absolutely required for CIP2A expression in cervical, endometrial and liver carcinoma cell lines. Thus, different factors regulate CIP2A expression in a cell-type specific manner. As previous work has shown a requirement for only Ets1 in prostate and gastric carcinomas, our results now indicate that CIP2A regulation is more complex than previously determined.

Entities:  

Keywords:  CIP2A; Elk1; Ets1; PP2A; biomarkers; cancer; p90

Mesh:

Substances:

Year:  2012        PMID: 23117818      PMCID: PMC3630189          DOI: 10.4161/trns.22518

Source DB:  PubMed          Journal:  Transcription        ISSN: 2154-1272


  53 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Structural studies of Ets-1/Pax5 complex formation on DNA.

Authors:  C W Garvie; J Hagman; C Wolberger
Journal:  Mol Cell       Date:  2001-12       Impact factor: 17.970

Review 3.  Ets-1 flips for new partner Pax-5.

Authors:  Miles A Pufall; Barbara J Graves
Journal:  Structure       Date:  2002-01       Impact factor: 5.006

4.  PROMO: detection of known transcription regulatory elements using species-tailored searches.

Authors:  Xavier Messeguer; Ruth Escudero; Domènec Farré; Oscar Núñez; Javier Martínez; M Mar Albà
Journal:  Bioinformatics       Date:  2002-02       Impact factor: 6.937

Review 5.  Oncogenes and tumor suppressor genes in prostate cancer.

Authors:  W Isaacs; T Kainu
Journal:  Epidemiol Rev       Date:  2001       Impact factor: 6.222

6.  Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family.

Authors:  Peter C Hollenhorst; Atul A Shah; Christopher Hopkins; Barbara J Graves
Journal:  Genes Dev       Date:  2007-07-24       Impact factor: 11.361

7.  ETS-1 transcription factor binds cooperatively to the palindromic head to head ETS-binding sites of the stromelysin-1 promoter by counteracting autoinhibition.

Authors:  David Baillat; Agnès Bègue; Dominique Stéhelin; Marc Aumercier
Journal:  J Biol Chem       Date:  2002-05-28       Impact factor: 5.157

8.  Complexities in ETS-domain transcription factor function and regulation: lessons from the TCF (ternary complex factor) subfamily. The Colworth Medal Lecture.

Authors:  Andrew D Sharrocks
Journal:  Biochem Soc Trans       Date:  2002-04       Impact factor: 5.407

9.  Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer.

Authors:  Linda Soo Hoo; Jianying Y Zhang; Edward K L Chan
Journal:  Oncogene       Date:  2002-07-25       Impact factor: 9.867

10.  Prognostic role of CIP2A expression in serous ovarian cancer.

Authors:  C Böckelman; H Lassus; A Hemmes; A Leminen; J Westermarck; C Haglund; R Bützow; A Ristimäki
Journal:  Br J Cancer       Date:  2011-09-06       Impact factor: 7.640

View more
  15 in total

1.  Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells.

Authors:  Rajash Pallai; Aishwarya Bhaskar; Natalie Barnett-Bernodat; Christina Gallo-Ebert; Michelle Pusey; Joseph T Nickels; Lyndi M Rice
Journal:  Tumour Biol       Date:  2015-04-02

2.  Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin.

Authors:  Rajash Pallai; Aishwarya Bhaskar; Natalie Barnett-Bernodat; Christina Gallo-Ebert; Joseph T Nickels; Lyndi M Rice
Journal:  Tumour Biol       Date:  2015-03-04

3.  Feedback between E2F1 and CIP2A regulated by human papillomavirus E7 in cervical cancer: implications for prognosis.

Authors:  Xiao Wang; Peng Gao; Meng Wang; Jing Liu; Jiaxiang Lin; Shule Zhang; Yiwei Zhao; Jingwen Zhang; Wei Pan; Zeyu Sun; Feifei Sun; Weiming Zhao; Chenghao Guo; Qingwei Wang
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

4.  Protein phosphatase 2A (PP2A) regulates low density lipoprotein uptake through regulating sterol response element-binding protein-2 (SREBP-2) DNA binding.

Authors:  Lyndi M Rice; Melissa Donigan; Muhua Yang; Weidong Liu; Devanshi Pandya; Biny K Joseph; Valerie Sodi; Tricia L Gearhart; Jenny Yip; Michael Bouchard; Joseph T Nickels
Journal:  J Biol Chem       Date:  2014-04-26       Impact factor: 5.157

5.  Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors:  C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

6.  Inhibition of protein methylesterase 1 decreased cancerous phenotypes in endometrial adenocarcinoma cell lines and xenograft tumor models.

Authors:  Michelle Pusey; Sophie Bail; Yan Xu; Olesia Buiakova; Mariya Nestor; Jing-Jing Yang; Lyndi M Rice
Journal:  Tumour Biol       Date:  2016-04-05

7.  Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.

Authors:  Ting-Ting Chao; Cheng-Yi Wang; Yen-Lin Chen; Chih-Cheng Lai; Fang-Yu Chang; Yi-Ting Tsai; Chung-Hao H Chao; Chung-Wai Shiau; Yuh-Chin T Huang; Chong-Jen Yu; Kuen-Feng Chen
Journal:  Oncotarget       Date:  2015-02-10

8.  Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.

Authors:  Chun-Yu Liu; Man-Hsin Hung; Duen-Shian Wang; Pei-Yi Chu; Jung-Chen Su; Tsung-Han Teng; Chun-Teng Huang; Ting-Ting Chao; Cheng-Yi Wang; Chung-Wai Shiau; Ling-Ming Tseng; Kuen-Feng Chen
Journal:  Breast Cancer Res       Date:  2014-09-17       Impact factor: 6.466

9.  Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.

Authors:  H-C Yu; M-H Hung; Y-L Chen; P-Y Chu; C-Y Wang; T-T Chao; C-Y Liu; C-W Shiau; K-F Chen
Journal:  Cell Death Dis       Date:  2014-07-31       Impact factor: 8.469

Review 10.  Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.

Authors:  Pradip De; Jennifer Carlson; Brian Leyland-Jones; Nandini Dey
Journal:  Oncotarget       Date:  2014-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.